HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G fragrances

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble will terminate a fragrance distribution agreement with Clarins effective Dec. 31, 2005, Clarins announces June 29. French beauty firm has distributed P&G's Hugo Boss, Giorgio, Jean Patou, Lacoste and Valentino brands in the U.S. market for six years. P&G says it has not made any decisions about how the brands will be distributed in the future, but the move follows the acquisition of Wella, which distributes fragrances under its Cosmopolitan Cosmetics division. Clarins "remains open to possible new ventures, either with P&G with whom discussions are continuing, or with other partners," the company states. With combined sales of approximately $50 mil. in the U.S. in 2004, Clarins' own Thierry Mugler and Azzaro brands "have now reached the critical mass that justifies an independent structure," the firm says, adding the futures of those brands are not in question...

You may also be interested in...



Hugo Boss Scent Portfolio Grows With Boss Soul, Del Mar Offerings

The launch of Boss Soul, the latest men's scent under the Hugo Boss franchise, will be supported with an aggressive promotional campaign, according to Clarins, the brand's U.S. distributor

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel